Celiprolol Treatment of Patients With Vascular Ehlers-Danlos Syndrome

Introduction: Vascular Ehlers-Danlos syndrome (vEDS) is a monogenetic disease caused by a mutation in procollagen 3A1. Clinical manifestations are arterial ruptures and dissections, as well as spontaneous ruptures of the colon, oesophagus and uterus. Expected survival is short, in historical cohorts approximately 50 years. In 2010 a French-Belgian randomized controlled trial (RCT), including 53 patients, reported a hazard ratio of only 0.36 of arterial events if patients were treated with the betablocker celiprolol [1], combining β1-adrenoceptor antagonist and β2-adrenoceptor agonist actions.

Source: European Journal of Vascular and Endovascular Surgery - November 30, 2019 Category: Surgery Authors: Hassan Baderkhan, Anna Stenborg, Anders H ägg, Anders Wanhainen, Martin Björck, Uppsala University Hospital Source Type: research